Bank Of Montreal Annovis Bio, Inc. Transaction History

Bank Of Montreal

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$5.27 - $15.46 $71,145 - $208,710	13,500 New	13,500 $108,000
Q4 2021 Feb 11, 2022	SELL	$17.58 - $37.67 $167,009 - $357,865	-9,500 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$30.95 - $120.97 $294,025 - $1.15 Million	9,500 New	9,500 $318,000

2.08M

88.1K

188K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $12.1M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.